GHK-Cu: Real Topical Evidence, an Unstudied Injectable Use

The short version

GHK-Cu is a naturally occurring tripeptide (glycyl-histidyl-lysine) bound to a copper ion, found in human plasma, saliva, and urine. It declines with age — from roughly 200 ng/mL at age 20 to about 80 ng/mL by age 60 ^[11]. As a topical ingredient (often labeled Copper Tripeptide-1), it is a legal, widely used cosmetic compound with a genuine multi-decade research trail on skin firmness, collagen, and wrinkle depth.

That is the key distinction on this page: GHK-Cu's strongest evidence is topical. Injecting it, or otherwise dosing it systemically, is a different and essentially unstudied use — the closest available data is a rat pharmacokinetic study, not a human one. This page separates the two uses clearly and never recommends a dose for either.

What it is

GHK-Cu is a linear tripeptide (Gly-His-Lys) chelated 1:1 to a Cu(II) ion through the histidine imidazole nitrogen, the glycine alpha-amino nitrogen, and the deprotonated glycine-histidine amide nitrogen, leaving the lysine side chain free (molecular formula C14H23CuN6O4+, a cationic complex). The GHK sequence occurs endogenously within the alpha-2(I) chain of type I collagen and in the protein SPARC/osteonectin — meaning the body already produces a version of this signal as part of normal tissue turnover.

A human skin-penetration study found that copper applied as the GHK-Cu tripeptide penetrates dermatomed skin with a permeability coefficient of 2.43 ± 0.51 × 10⁻⁴ cm/h; over 48 hours, 136.2 ± 17.5 µg/cm² of copper permeated and 97 ± 6.6 µg/cm² was retained as a dermal depot ^[12] — the physical basis for topical formulation.

How it works

GHK-Cu acts as both a copper chaperone and a pleiotropic signaling molecule. At picomolar-to-nanomolar concentrations it directly stimulates dermal fibroblasts to synthesize collagen, elastin, glycosaminoglycans, and the proteoglycan decorin, while rebalancing matrix metalloproteinases against their tissue-inhibitor counterparts (TIMPs) ^[11]. The copper ion itself enables lysyl-oxidase-mediated collagen and elastin cross-linking and has superoxide-dismutase-like antioxidant activity.

Gene-expression analysis reports that GHK alters expression of roughly 31.2% of human genes at a 50%-or-greater change threshold (59% up, 41% down), upregulating wound-repair, DNA-repair, antioxidant, and ubiquitin-proteasome pathways and suppressing NF-kB-driven inflammation ^[9]. A widely repeated figure describing GHK as affecting roughly 4,000 genes is an extrapolation beyond this verified threshold — the properly qualified statistic covers on the order of 2,100 genes.

What the research shows

Anti-wrinkle efficacy, the freshest synthesis. A 2025 review confirms GHK's poor stratum-corneum permeability (clogP -2.24) as the central delivery challenge, and reports that procollagen synthesis increased in 70% of GHK-Cu-treated subjects versus 50% for vitamin C and 40% for retinoic acid in the studies it reviewed. It also evaluates palmitoylation (Pal-GHK) and microneedle pretreatment as delivery-enhancement strategies — microneedling let roughly 134 nmol of GHK permeate versus none through intact skin ^[8].

Gene-expression breadth. The Connectivity Map analysis described above found GHK modulates roughly 31.2% of human genes at a 50%-or-greater threshold, with strong stimulation of the ubiquitin-proteasome system (41 genes up, only 1 down) alongside DNA-repair and antioxidant gene sets ^[9].

The strongest controlled human trial. In a 6-month trial of 45 men with androgenetic alopecia (Norwood-Hamilton stage II-V), a complex of 5-aminolevulinic acid and glycyl-histidyl-lysine peptide increased hair count by 52.6 (at 100 mg/mL) and 71.5 (at 50 mg/mL) versus 9.6 for placebo (p<0.05), with no adverse events in any group ^[10]. This is the single strongest controlled efficacy signal for a GHK-containing topical on this desk — though it tests a combination product, not GHK-Cu alone.

Canonical skin-regeneration review. Beyond hair, GHK-Cu's skin-regeneration profile includes documented, placebo-controlled improvements in skin laxity, clarity, fine-line depth, and density, alongside its stimulation of collagen, dermatan sulfate, chondroitin sulfate, and decorin synthesis ^[11].

Reported effects, cautions & safety

People in skincare and research-peptide communities report a broad, mostly cosmetic effect cluster with topical copper-peptide products. These accounts are anecdotal, not clinical evidence, compiled from skincare forums, brand product-review pages, and community guides.

Reported benefits (anecdotal, not clinical evidence): firmer, tighter-feeling skin is the most commonly sought effect, building gradually over several weeks of twice-daily use. Users also frequently describe softer fine lines and shallower wrinkles over six to twelve weeks, better hydration and a plumper look within the first one to two weeks, and smoother texture with a brighter overall look. Some report more even skin tone, calmer-looking skin after cosmetic procedures or on scars, and — with scalp use, often alongside microneedling — less hair shedding and thicker-looking hair. A smaller group describes reconstituting GHK-Cu for injectable research use and reports changes in skin quality, though there is no validated human data behind these accounts.

Reported adverse effects (anecdotal, not clinical evidence): skin irritation — redness, itching, stinging, or dryness — is the most common complaint, especially at high concentration or frequent application. Some acne-prone users describe a temporary breakout or purging phase. A small number describe skin looking duller rather than better, a phenomenon nicknamed the copper uglies in community shorthand, and a minority with existing dark spots report temporary darkening of pigment. A very common practical complaint is that copper peptides seem to stop working, or cause irritation, when layered with vitamin C, strong acids, or retinol in the same routine. Among the smaller group using it by injection, injection-site reactions are the most-reported issue.

Cited cautions from the clinical literature:

• Injectable and systemic use is unapproved and unstudied in humans. The topical cosmetic safety record does not extend to injecting or otherwise systemically dosing GHK-Cu.
• Copper accumulation risk with prolonged systemic use is a theoretical, mechanism-based concern, particularly relevant to people with copper-handling conditions such as Wilson's disease.
• Pigmentation changes are a possibility for people prone to dark spots or melasma, since copper supports the pigment-producing enzyme tyrosinase.
• Skin irritation is more likely at high concentration or on sensitive skin; patch-testing and easing in slowly is the common-sense approach.
• Do not combine with vitamin C, strong acids, or other low-pH actives in the same step — this can break apart the copper-peptide complex, wasting both products and stacking irritation ^[8].
• Human evidence is limited and mostly small topical studies; broader anti-aging and gene-level claims come largely from cell, rodent, and database studies, and marketing regularly outpaces the controlled human evidence ^[8][11].

Where it fits in recovery & tissue-repair research

GHK-Cu occupies a genuinely different evidentiary position from the other three compounds here: it has real, controlled human trial data — but almost entirely for topical, cosmetic use. Its matrix-remodeling and collagen-stimulating mechanism is the reason it appears in the GLOW blend, alongside BPC-157's angiogenic profile and TB-500's cell-migration signal. Reading GHK-Cu on its own terms first makes clear which part of GLOW's marketing rests on real human evidence, and which part is extrapolation. See the comparison page for the side-by-side.